(Q36315580)

13 August 2017

1 reference

title

Recent progress in the battle between oncolytic viruses and tumours (English)

1 reference

13 August 2017

1 reference

4

John C Bell

1 reference

13 August 2017

Kelley A Parato

1

1 reference

13 August 2017

Donna Senger

series ordinal

2

1 reference

13 August 2017

Peter A J Forsyth

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

13 August 2017

Nature Reviews Cancer

1 reference

13 August 2017

5

1 reference

13 August 2017

965-976

1 reference

13 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1750

13 August 2017

0 references

cites work

Recombinant measles virus requiring an exogenous protease for activation of infectivity

1 reference

Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial

21 January 2018

1 reference

HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer

21 January 2018

1 reference

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

31 March 2020

1 reference

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

31 March 2020

1 reference

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

31 March 2020

1 reference

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

31 March 2020

1 reference

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

31 March 2020

1 reference

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

31 March 2020

1 reference

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

31 March 2020

1 reference

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy

31 March 2020

1 reference

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

31 March 2020

1 reference

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

31 March 2020

1 reference

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

31 March 2020

1 reference

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

31 March 2020

1 reference

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

31 March 2020

1 reference

CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus

31 March 2020

1 reference

Recombinant measles viruses efficiently entering cells through targeted receptors

31 March 2020

1 reference

Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen

31 March 2020

1 reference

An oncolytic measles virus engineered to enter cells through the CD20 antigen

31 March 2020

1 reference

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

31 March 2020

1 reference

Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule

31 March 2020

1 reference

Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model

31 March 2020

1 reference

Antibody-targeted cell fusion

31 March 2020

1 reference

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

31 March 2020

1 reference

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

31 March 2020

1 reference

Targeted gene delivery by tropism-modified adenoviral vectors

31 March 2020

1 reference

Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors

31 March 2020

1 reference

Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy

31 March 2020

1 reference

Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells

31 March 2020

1 reference

Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.

31 March 2020

1 reference

Stromelysin-1 (MMP-3) is inducible in T lymphoma cells and accelerates the growth of lymphoid tumors in vivo

31 March 2020

1 reference

Oncolysis of human ovarian cancers by echovirus type 1.

31 March 2020

1 reference

Intergeneric poliovirus recombinants for the treatment of malignant glioma

31 March 2020

1 reference

The human poliovirus receptor. Receptor-virus interaction and parameters of disease specificity.

31 March 2020

1 reference

Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus

31 March 2020

1 reference

Rescue and propagation of fully retargeted oncolytic measles viruses

31 March 2020

1 reference

Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction

31 March 2020

1 reference

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

31 March 2020

1 reference

Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon.

31 March 2020

1 reference

A critical function for type I interferons in cancer immunoediting

31 March 2020

1 reference

The roles of IFN gamma in protection against tumor development and cancer immunoediting

31 March 2020

1 reference

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

31 March 2020

1 reference

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

31 March 2020

1 reference

VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway

31 March 2020

1 reference

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

31 March 2020

1 reference

Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses

31 March 2020

1 reference

Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.

31 March 2020

1 reference

Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis

31 March 2020

1 reference

Newcastle disease virus V protein is a determinant of host range restriction

31 March 2020

1 reference

Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants

31 March 2020

1 reference

Lost in translation: dysregulation of cap-dependent translation and cancer

31 March 2020

1 reference

Targeting mTOR signaling for cancer therapy

31 March 2020

1 reference

Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts

31 March 2020

1 reference

Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.

31 March 2020

1 reference

Targets and mechanisms for the regulation of translation in malignant transformation

31 March 2020

1 reference

RNA sensors: novel regulators of gene expression

31 March 2020

1 reference

Regulation of eIF2alpha phosphorylation by different functions that act during discrete phases in the herpes simplex virus type 1 life cycle

31 March 2020

1 reference

PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone.

31 March 2020

1 reference

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

31 March 2020

1 reference

Defective translational control facilitates vesicular stomatitis virus oncolysis

31 March 2020

1 reference

Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L.

31 March 2020

1 reference

Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon

31 March 2020

1 reference

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

31 March 2020

1 reference

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

31 March 2020

1 reference

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

31 March 2020

1 reference

Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.

31 March 2020

1 reference

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

31 March 2020

1 reference

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

31 March 2020

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

31 March 2020

1 reference

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

31 March 2020

1 reference

Resistance to viral infection of super p53 mice.

31 March 2020

1 reference

Flavivirus Activates Phosphatidylinositol 3-Kinase Signaling To Block Caspase-Dependent Apoptotic Cell Death at the Early Stage of Virus Infection

31 March 2020

1 reference

Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication

31 March 2020

1 reference

The baculovirus anti-apoptotic protein Op-IAP does not inhibit Drosophila caspases or apoptosis in Drosophila S2 cells and instead sensitizes S2 cells to virus-induced apoptosis

31 March 2020

1 reference

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency

31 March 2020

1 reference

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

31 March 2020

1 reference

Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L.

31 March 2020

1 reference

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

31 March 2020

1 reference

Extracellular enveloped vaccinia virus escapes neutralization

31 March 2020

1 reference

Antibody neutralization of the extracellular enveloped form of vaccinia virus

31 March 2020

1 reference

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

31 March 2020

1 reference

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

31 March 2020

1 reference

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

31 March 2020

1 reference

Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat.

31 March 2020

1 reference

Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung.

31 March 2020

1 reference

Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver

31 March 2020

1 reference

In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer

31 March 2020

1 reference

Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

31 March 2020

1 reference

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.

31 March 2020

1 reference

Cellular receptor interactions of C-cluster human group A coxsackieviruses

31 March 2020

1 reference

Complexes of poliovirus serotypes with their common cellular receptor, CD155

31 March 2020

1 reference

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus

31 March 2020

1 reference

The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes

31 March 2020

1 reference

Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection

31 March 2020

1 reference

Development and assessment of human adenovirus type 11 as a gene transfer vector

31 March 2020

1 reference

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

31 March 2020

1 reference

Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines

31 March 2020

1 reference

PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability

31 March 2020

1 reference

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

31 March 2020

1 reference

Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response

31 March 2020

1 reference

Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

31 March 2020

1 reference

Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer

31 March 2020

1 reference

Preferential targeting of vesicular stomatitis virus to breast cancer cells.

31 March 2020

1 reference

Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication

31 March 2020

1 reference

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

31 March 2020

1 reference

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

31 March 2020

1 reference

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

31 March 2020

1 reference

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1750

1 reference

13 August 2017

1 reference